ClinicalTrials.gov is best treated as a complement to journal publications, not a replacement. For semaglutide and tirzepatide weight-loss comparisons, it can add protocol-level details and posted summary results, but it does not by itself provide a complete or fully validated comparative evidence base[1][2][3].
The registry is useful because each trial record has a unique NCT identifier, structured registration fields, a History of Changes, and a separate results database that can include participant flow, baseline characteristics, outcome measures, analyses, adverse events, and restrictive agreements. That makes it valuable for checking what was planned versus what was reported, and for spotting missing or shifted outcome information[4][5].
This compact view separates the registry value from its main interpretation risks when comparing the two drugs.
| What reviewers can extract | What they should verify | What should be treated cautiously |
|---|---|---|
| Protocol basics: purpose, recruitment status, design, eligibility criteria, locations, and other registration details[6] | Whether the posted record matches the journal paper's final design, population, and endpoint definitions[7][8] | Any inference that the registry record alone settles comparative efficacy between semaglutide and tirzepatide[9] |
| Summary results: participant flow, baseline characteristics, outcome measures, statistical analyses, and adverse events[10] | Whether the analysis population is consistent across fields and whether the outcome definition is sufficiently specific[11][12] | Imprecise outcome labels or internally inconsistent entries that can blur true between-trial comparability[13][14] |
| Change history and reporting constraints, including sponsor-investigator agreements that may restrict dissemination[15][16] | Whether missing fields are due to nonreporting, delayed updates, or later corrections[17] | Assuming the public record is complete, current, or independently verified in all details[18] |
Practical implication: use ClinicalTrials.gov to identify trial existence, planned design, and posted summary results, then verify the final outcome definitions, analysis populations, and any discrepancies against the journal article or other source of record before making comparative claims[28][29].
For semaglutide versus tirzepatide weight-loss evidence, ClinicalTrials.gov adds transparent protocol and summary-results information that journals may not fully expose, but it is not a standalone basis for causal comparison. The safest reading is: extract the registry facts, verify them against publication-level detail, and treat missing, inconsistent, self-reported, or incompletely covered records as evidence gaps rather than as neutral findings[30][31][32][33].
Get more accurate answers with Super Pandi, upload files, personalized discovery feed, save searches and contribute to the PandiPedia.
Let's look at alternatives: